European Institute of Oncology / Istituto Europeo di Oncologia (IEO)

Research / Science organisation

Location: Milano / Mailand, Italy (IT)

ISNI: 0000000417570843

ROR: https://ror.org/02vr0ne26

Show on Map:

Publications

(85)

Research Grants

(1)

Unmet medical needs in metastatic lung and digestive neuroendocrine neoplasms (2019) Capdevila J, Bodei L, Davies P, Gorbounova V, Jensen RT, Knigge UP, Krejs GJ, et al. Journal article Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) (2018) Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, et al. Conference contribution mHealth and telemedicine apps: in search of a common regulation (2018) Crico C, Renzi C, Graf N, Buyx A, Kondylakis H, Koumakis L, Pravettoni G Journal article The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity (2018) Colombo M, Lopez-Perolio I, Meeks HD, Caleca L, Parsons MT, Li H, De Vecchi G, et al. Journal article Development and validation of the SIMPLE endoscopic classification of diminutive and small colorectal polyps (2018) Iacucci M, Trovato C, Daperno M, Akinola O, Greenwald D, Gross SA, Hoffman A, et al. Journal article Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment (2018) Yao JC, Fazio N, Li D, Pavel ME, Strosberg J, Bergsland E, Ruszniewski P, et al. Conference contribution Efficacy and safety of nilotinib in patients with kit-mutated metastatic or inoperable melanoma: Final results from the global, single-arm, phase ii team trial (2017) Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, et al. Journal article Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study (2017) Higgins M, Curigliano G, Dieras V, Kuemmel S, Kunz G, Fasching P, Campone M, et al. Journal article PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1 (2017) Jiao X, Aravidis C, Marikkannu R, Rantala J, Picelli S, Adamovic T, Liu T, et al. Journal article

‹ 1 ... 4 5 6 7 8 9 ›